Health Blog

Tips | Recommendations | Reviews

What is mavyret medication price disclosure outside of insurance?

what is mavyret medication price disclosure outside of insurance
If you are concerned about the price of MAVYRET, you have choices. – * Cure is defined as no detectable hep C virus in the blood three months after therapy finishes. Individual outcomes might vary. As of January 2022, the advertised price, also known as the Wholesale Acquisition Cost (WAC), for one month of MAVYRET is $13,200.00.

If you have: You could pay:
$ 20
Medicaid $ 20 $20.00 or less per month, depending on state plan
Commercial Insurance (usually provided by employer) (Blue Cross Blue Shield, Aetna, etc) As little as $5 a month with MAVYRET Savings Card
Medicare: Part D $660.00-3,081.00 per month, depending on coverage phase Most Medicare patients have Standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1-877-628-9738 . Monthly out-of-pocket cost for MAVYRET may vary depending on patient’s other medication costs.
Medicare: Low-Income Subsidy (LIS) $9.85 per month starting January 1, 2022
Uninsured or having difficulty paying for your medication myAbbVie Assist provides AbbVie medicines to qualifying patients. Visit or call 1-800-222-6885 to learn more.
Other Insurance (VA, DOD, TRICARE, others) Because coverage varies by plan, call 1-877-628-9738 to speak to an Insurance Specialist to find out how much MAVYRET will cost you.
*Important Details About Understanding Your Individual Costs: The chart above provides cost information based on what a person with the type of coverage listed may pay for a 4-week supply of MAVYRET. Your type of health or prescription insurance plan will determine exactly how much you will pay.

Does drinking effect Mavyret?

Alcohol use by people with hepatitis C virus (HCV) may hasten the development of cirrhosis and liver cancer. Mavyret (glecaprevir-pibrentasvir) is used to treat advanced HCV in individuals. Because alcohol consumption is associated with a more faster development of liver disease, physicians normally recommend that all HCV patients refrain from drinking.

  • Hepatitis C virus (HCV) and drinking are significant causes of liver damage in the United States and worldwide.
  • In Mavyret’s product labeling, there is no mention of a particular drug-alcohol (ethanol) interaction.
  • In studies of antivirals for HCV therapy, patients were often asked to abstain from or restrict alcohol consumption; hence, the clinical consequences of mixing alcohol with these regimens remain unknown.

Unknown is the precise amount of alcohol that might exacerbate liver damage in HCV patients.